plasma supar levels are associated with mortality, admission time, and charlson comorbidity index in the acutely admitted medical patient a prospective observational study等离子体supar水平与死亡率相关,入学时间,charlson发病率指数在敏锐地承认医学患者前瞻性观察性研究.pdfVIP

Haupt et al. Critical Care 2012, 16:R130 /content/16/4/R130 RESEARCH Open Access Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study 1* 1 2 1 Thomas Huneck Haupt , Janne Petersen , Gertrude Ellekilde , Henrik Hedegaard Klausen , Christian Wandall Thorball1, Jesper Eugen-Olsen1 and Ove Andersen1 Abstract Introduction: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane- bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/ Charlson Comorbidity Index Score, and mortality. Methods: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR’s association with these endpoints. Results: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml